CDMOHUBCDMOHUB
Pricing
    CDMOHUBCDMOHUB
    Pricing
    CDMOHUBCDMOHUB
    Pricing
    Blog/Briefing
    BriefingFriday Brief · Aseptic Fill-Finish

    Same Label, Different Filling Line: Five Questions on Aseptic Fill-Finish

    Two CDMOs can both list “aseptic fill-finish” and offer very different manufacturing setups. These five questions help sponsors see what sits behind the label.

    By CDMO Hub·20 November 2026·3 min read·638 words
    Fill-FinishSterile ManufacturingPartner Selection
    Also available as a designed 2-page PDFGet it →

    “Aseptic fill-finish” is one of the most common capabilities on a CDMO’s website. It is also one of the least specific. The same two words can describe a modern isolator line with robotic filling, or an older line where operators work in a conventional cleanroom.

    Newer filling lines increasingly combine isolators, robotics and modular designs. These can reduce the need for people near exposed product, the main source of contamination in aseptic work. But the newest line is not automatically the right one. For a sponsor, two questions matter more: does the proposed line fit the product, and how does the site control contamination risk on it?

    The rules have moved

    The revised EU GMP Annex 1, which governs sterile manufacturing, came into effect on 25 August 2023. It requires each site to have a contamination control strategy (CCS). This is one document showing how facility design, procedures, monitoring and people work together to prevent contamination.

    Annex 1 encourages barrier systems such as isolators and RABS but does not mandate them. A site that uses other approaches must justify them in its CCS. That gives sponsors a useful starting point: a compliant site should be able to explain its approach line by line.

    Five questions for a first conversation

    1. What barrier technology does the proposed line use?

    Is the line an isolator, a restricted access barrier system (RABS) or a conventional cleanroom? An isolator is a sealed enclosure, decontaminated automatically, that operators reach only through gloves. A RABS is a rigid barrier with glove ports; “open” versions allow doors to be opened under defined conditions, “closed” versions do not.

    Ask how operator interventions are managed and how often they happen. Each intervention is a moment when product can be exposed.

    2. How does the site’s contamination control strategy apply to this line?

    A CCS covers the whole facility. Ask how it applies to the line you would use: which risks were identified, which controls address them, and how monitoring results feed back into the strategy. A specific answer is a good sign. A general description of the quality system is not.

    3. What do recent aseptic process simulations show?

    An aseptic process simulation, or media fill, runs the filling process with sterile growth medium in place of product. The filled units are then incubated and checked for microbial growth. Ask for recent results on the specific line, any relevant deviations, and how they were investigated and addressed.

    Ask too whether the simulations covered the interventions and run the lengths your product would need.

    4. Does the line fit your product and process?

    A strong line can still be the wrong line. Check the container types it handles, such as vials, syringes or cartridges, and the batch sizes it runs efficiently. Confirm whether your process is liquid filling only or includes freeze-drying (lyophilisation). If your compound is highly potent, ask how the line protects operators as well as product.

    A mismatch here can mean buying and qualifying new machine parts, extra validation or a later transfer. Each one costs time.

    5. What is the inspection history of the actual filling site?

    Large CDMO groups run many sites, and their records differ. Ask about recent inspections at the site and line you would use: what was found, how it was resolved, and whether anything remains open. A strong group-wide record does not answer this question.

    The takeaway

    The label “aseptic fill-finish” tells you a CDMO is in the market, not whether it suits your product. Asking these five questions early lets you have a meaningful like-for-like comparison, and avoid discovering a mismatch after technology transfer has started.

    CDMO Hub currently lists 358 company profiles with aseptic filling capabilities. Use cdmohub.ai to build an initial shortlist, then bring these questions to your first conversations.

    The PDF edition

    Get this briefing as a designed 2-page PDF

    You have just read the whole thing. The PDF is the same analysis, typeset for circulation — the version to forward to your sterile manufacturing lead or drop into a partner-selection pack.

    • 2 pages, print-ready, with the full source list
    • The five questions to take into your first CDMO conversation
    • Optional: future issues, roughly monthly

    We will email the PDF to this address. That is what this form does.

    We never sell or share your address. Privacy notice

    Directories in this article

    Fill-Finish CDMOs · Aseptic Processing CDMOs · Lyophilization CDMOs

    ← Back to the blog

    The PDF edition

    Same post, typeset for circulation. Work email, and it is in your inbox.

    Get the PDF

    2 pages · 274 KB

    CDMOHUB

    Connecting biotech and pharma teams with contract manufacturing partners worldwide.

    Platform

    • Find CDMOs
    • CDMO Matchmaking
    • Expert Matchmaking
    • SmartRFI
      Members
    • Modality Guides
    • Supplier Maps
    • Join as Partner

    Company

    • Blog
    • Briefings
    • About Us
    • Contact

    Legal

    • Terms of Service
    • Privacy Policy

    © 2026 CDMOHUB. All rights reserved.

    CDMO Hub, Inc. Registered in Delaware, USA